In Phase II Clinical Trials
Development of Effective and Innovative Medicines to Address the needs of Patients and Improve their Health, Longevity and Quality of Life.
Hub Controls
  • Demo Video
  • Upload Photo
  • Edit Company Profile
  • Add a Link
  • Update Fast Facts
  • Add Management Bios
  • Private Messages
  • Edit My Profile
  • View/Edit My Portfolio

Email Updates

AGORACOM News Flash

2 Big Announcements On AGORACOM Blog Today:

1]  Billionaire Investor, George Soros, Takes 5.19% Stake (11.7 million shares) In AGORACOM Client. Which Company? Full Story Here.

2] AGORACOM Acquires www.Grandich.com and Appoints Peter Grandich As Chief Commentator. Full Story Here.  New Grandich Blog Here.

Regards,
George

 

AlphaRx > Message
Moneyshirt

Re: Indaflex Phase III

Posted by: jackfree on January 16, 2008 12:12PM

In response to: Re: Indaflex Phase III by markak15

In the last year or so ALRX started to change their business model. What they do now is set up licensing fees for their technology. In the case of Indaflex, Proprius pays for all costs related to bringing it to market. The Milestone payments go to the company as regular revenue. They may choose to use it for other research into products not currently being funded. I don't know what the burn through rate would be but, it should not be an issue. Proprius would make another much larger payment after Phase III. From what you found out that would be in early 2009, I believe it is for over $11 Million. Later when the product enters the market Proprius would pay other milestone payments based on sales.
Post a Reply

Please login to reply to this message.

Executive Address
Alrxsmall
Michael Lee
President
May 18, 2006

 

Michael Lee provides the investor community an update on recent events

View Broadcast

Stock Quote